| abstract |
Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection. The methods can be conducted by administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment. |